Trichinosis medical therapy

Jump to navigation Jump to search

Trichinosis Microchapters


Patient Information


Historical perspective




Differentiating Trichinosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies


Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Trichinosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Trichinosis medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Trichinosis medical therapy

CDC on Trichinosis medical therapy

Trichinosis medical therapy in the news

Blogs on Trichinosis medical therapy

Directions to Hospitals Treating Trichinosis

Risk calculators and risk factors for Trichinosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Danitza Lukac


The mainstay of therapy for trichinosis are anthelmintics drugs such as albendazole or mebendazole.[1]

Medical Therapy

Treatment for asymptomatic, abortive and mild patients:

Treatment for pronounced and severe patients:

Antihelmintic Regimen[1]

Trichinosis in adult and children ≥2yrs of age
  • Preferred regimen (1): Albendazole 400 mg PO bid for 8 to 14 days OR Mebendazole 200-400 mg PO tid for 3 days, then 400-500 mg PO tid for 10 days
  • Note:
    • Albendazole:
      • Pregnancy: Albendazole is pregnancy category C.
      • Lactation: It is not known whether albendazole is excreted in human milk.
      • Pedriatic patients: The safety of albendazole in children less than 6 years old is not certain. Studies of the use of albendazole in children as young as one year old suggest that its use is safe.
    • Mebendazole:
      • Pregnancy: Mebendazole is in pregnancy category C.
      • Lactation: It is not known whether mebendazole is excreted in breast milk. The WHO classifies mebendazole as compatible with breastfeeding and allows the use of mebendazole in lactating women.
      • Pedriatic patients: The safety of mebendazole in children has not been established.


  1. 1.0 1.1 Trichinellosis. CDC. Accessed on January 26, 2016
  2. Gottstein B, Pozio E, Nöckler K (2009). "Epidemiology, diagnosis, treatment, and control of trichinellosis". Clin Microbiol Rev. 22 (1): 127–45, Table of Contents. doi:10.1128/CMR.00026-08. PMC 2620635. PMID 19136437.

Template:WH Template:WS